ASTH
Astrana Health, Inc.
ASTH's fundamentals are strong: revenue grew 35% and earnings per share more than tripled. At 30x earnings, it's trading below its usual 34x. Analysts expect that strong growth to continue, though they disagree widely on how much.
ASTH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Stable |
ASTH's revenue and profitability are currently healthy, and its cash flow and balance sheet are stable.
ASTH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $31.77 | — |
| Cheap | 26x | $28.12 | -11% |
| Current | 30x | $31.77 | — |
| Fair | 34x | $35.99 | +13% |
| Expensive | 61x | $65.79 | +107% |
Historical ranges are pointers, not guarantees.
ASTH's PE is in its cheap range at 30x. If earnings grow as analysts expect, today's price would be 18x next year's earnings.
ASTH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for ASTH, with profitability improving. However, they disagree widely on these estimates.
ASTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.77 | +65% |
| Q3 2026 | $1.07 | +435% |
| Q2 2026 | $0.82 | +58% |
| Q1 2026 | $0.61 | -16% |
| Q4 2025 | $0.46 | -49% |
| Q3 2025 | $0.20 | -85% |
| Q2 2025 | $0.52 | -64% |
| Q1 2025 | $0.73 | -45% |
| Q4 2024 | $0.90 | -30% |
ASTH's earnings per share have fallen from their peak: $1.07 over the past year, against $1.64 in early 2022.
ASTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +7.1% |
| Q2 2026 | $972.5M | +49% |
| Q1 2026 | $965.1M | +56% |
| Q4 2025 | $950.5M | +43% |
| Q3 2025 | $956M | +100% |
| Q2 2025 | $654.8M | +35% |
| Q1 2025 | $620.4M | +53% |
| Q4 2024 | $665.2M | +88% |
ASTH's revenue has grown year over year for 23 quarters in a row: $1B last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.9% | +1.9 points |
| Q2 2026 | 3.5% | +0.4 points |
| Q1 2026 | 3% | -0.4 points |
| Q4 2025 | 1.9% | +1.8 points |
| Q3 2025 | 2% | -3.9 points |
| Q2 2025 | 3.1% | -3.1 points |
| Q1 2025 | 3.3% | -4.1 points |
| Q4 2024 | 0.1% | +1.2 points |
ASTH's operating margin was 3.9% last quarter, up 1.9 points from the same quarter a year ago.
ASTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.4M | +68% |
| Q2 2026 | $28.9M | -68% |
| Q1 2026 | $64.1M | +372% |
| Q4 2025 | -$6M | +$7.5M |
| Q3 2025 | $7.4M | -77% |
| Q2 2025 | $89.5M | +340% |
| Q1 2025 | $13.6M | +142% |
| Q4 2024 | -$13.5M | -210% |
ASTH generated $99M in free cash flow over the past year, up 2.5% from the year before.
ASTH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +138K shares |
| 1 year | +0.9% | +443K shares |
| 3 years | +6.4% | +3M shares |
| 5 years | +8.9% | +4.1M shares |
| Available history | +33% | +12.5M shares |
ASTH has 50M diluted shares, up 0.9% from a year ago, despite $19M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1M |
| Q2 2026 | — |
| Q1 2026 | $2.8M |
| Q4 2025 | $15M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $10.6M |
| Q4 2023 | $503,000 |
ASTH spent $19M buying back its own shares over the past year.
ASTH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.9x | Moderate |
| Q2 2026 | 3.3x | Elevated |
| Q1 2026 | 3.9x | Elevated |
| Q4 2025 | 4.9x | High |
| Q3 2025 | 6.0x | High |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.3x | Healthy |
ASTH's net debt is about 2.9 years of its operating earnings (EBITDA), down from 6.0 years a year ago.
ASTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.9 | Neutral |
| Stochastic | 28.8 | Neutral |
ASTH's weekly RSI is 41 (neutral) and its Stochastic is 29 (neutral).
ASTH PE vs Healthcare Sector
| Metric | ASTH | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 26x | 15% above |
| PE % | 30 | 29 | 1 pt above |
ASTH is trading at 30x earnings, a 15% premium to the Healthcare sector's median of 26x.
ASTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.9 | 11% below |
| 20 week MA | $38.4 | 17% below |
| 50 week MA | $32.8 | 3% below |
| 100 week MA | $31.0 | 2.6% above |
| 200 week MA | $35.1 | 9.6% below |
ASTH's trend is mixed: it's above one of its five weekly moving averages, and 9.6% below its 200-week average.
ASTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.7 | $17.5 | -6.3% |
| 2021 | $17.5 | $70.8 | +305% |
| 2022 | $70.8 | $29.9 | -58% |
| 2023 | $29.9 | $38.3 | +28% |
| 2024 | $38.3 | $32.7 | -15% |
| 2025 | $32.7 | $25.4 | -22% |
| 2026 YTD | $25.4 | $31.8 | +25% |
ASTH's yearly returns have swung widely, from +305% in 2021 to −58% in 2022. It's up 25% so far in 2026.